Skip to content

Examination of Psychological and Physiological Pathways Linking Gratitude and Pain

Examination of Psychological and Physiological Pathways Linking Gratitude and Pain and the Moderating Effects of COMT Genotype on These Associations

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06317844
Enrollment
145
Registered
2024-03-19
Start date
2024-09-10
Completion date
2025-08-19
Last updated
2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pain, Emotions, Positive Thinking

Brief summary

The goal of this clinical trial is to compare the effects of a brief gratitude intervention on individuals' psychological and physiological responses to acute pain. Furthermore, these associations will be examined in the context of genetic variations associated with both pain and psychological processes.

Detailed description

After being informed about the study and potential risks, all patients giving written informed consent will be randomized to a behavioral writing intervention and a cold pressor task. Participants will be randomized to a gratitude or neutral writing condition.

Interventions

BEHAVIORALBehavioral Writing Intervention

This behavioral intervention will require participants to write about certain aspects of their lives.

Sponsors

Black Hills State University
Lead SponsorOTHER
National Institute of General Medical Sciences (NIGMS)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* must be pain-free * must be at least 18 years old

Exclusion criteria

* cardiovascular disease * Raynaud's disease * epilepsy * being pregnant * having a current injury to or open cut or sore on one's non-dominant hand * history of fainting or seizures * history of frostbite in non-dominant hand * chronic pain conditions (e.g., fibromyalgia, neuropathy, arthritis) * diabetes * malignant tumor * chronic lung disease * liver disease * kidney disease * gastrointestinal diseases * currently taking opioids

Design outcomes

Primary

MeasureTime frameDescription
Change in Subjective Pain Ratings From Baseline to 10-minutes Post Cold Pressor TestBaseline to 10 minutes post cold pressor testSelf-reported measures of pain will be reported on a numeric scale of 0 (no pain) to 10 (strongest pain imaginable every 15 seconds throughout a cold pressor test and again 1 minute and 10 minutes post cold pressor test.
Differences in Pain Tolerance to Cold Pressor TestUp to 1.5 minutes of Cold Pressor TestPain tolerance will be measured in terms of how many seconds individuals can keep their hand submerged in near-freezing water, for a maximum of up to 90 seconds (the task will be ended at that point).
Differences in Pain Onset to Cold Pressor TestUp to 1.5 minutes of Cold Pressor TestPain onset will be measured in seconds between participants submerging their hands into near-freezing water and the self-reported beginning of pain.

Secondary

MeasureTime frameDescription
Differences in Pain-Related CognitionImmediately after the Cold Pressor TestThe Rumination and Reappraisal subscales from the Pain-Related Cognitive Processes Questionnaire were used to assess the extent to which individuals engaged in various thought processes during the cold pressor test. Each subscale is comprised of 6-items and answered on a 0 (Not at all) to 4 (All or most of the time) scale. Scores on each item are summed to calculate an overall score which can range from 0 to 24, with higher scores indicative of greater use of each cognitive process.
Differences in Autonomic Nervous System ResponsivityBaseline to 10 minutes post cold pressor testAutonomic nervous system responsivity will be assessed using levels of salivary alpha-amylase. Unstimulated whole saliva samples will be collected using the passive drool technique at the following time points: 1) immediately following completion of baseline surveys, 2) immediately following the experimental writing task, 3) 1-minute post-cold pressor test, and 4) 10-minutes post-cold pressor test.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORNathan Deichert, PhD

Black Hills State University

Participant flow

Recruitment details

Participants were recruited through the Black Hills State University community through posting flyers, electronic newsletters, and in-person announcements.

Pre-assignment details

Given that the intervention consisted of a single visit of approximately 45 minutes, there were no significant events that occurred between enrollment and assignment of participants to an intervention group.

Baseline characteristics

Characteristic
Age, Continuous22.27 Years
STANDARD_DEVIATION 8.79
Coping Strategies Questionnaire 2411.85 Units on a Scale
STANDARD_DEVIATION 5.47
GAD-74.69 Units on a Scale
STANDARD_DEVIATION 4.36
Perceived Stress Scale15.27 Units on a Scale
STANDARD_DEVIATION 6.86
Race (NIH/OMB)
American Indian or Alaska Native
6 Participants
Race (NIH/OMB)
Asian
5 Participants
Race (NIH/OMB)
Black or African American
3 Participants
Race (NIH/OMB)
More than one race
9 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
Race (NIH/OMB)
White
112 Participants
Self-Reported Smoking
Current Smoker
12 Participants
Self-Reported Smoking
Data Missing
0 Participants
Self-Reported Smoking
Non-Smoker
69 Participants
Sex: Female, Male
Female
104 Participants
Sex: Female, Male
Male
23 Participants
Socioeconomic Status
Lower Class
7 Participants
Socioeconomic Status
Middle Class
66 Participants
Socioeconomic Status
Not Reported
1 Participants
Socioeconomic Status
Upper Middle and Upper Class
14 Participants
Socioeconomic Status
Working Class
16 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 780 / 67
other
Total, other adverse events
1 / 780 / 67
serious
Total, serious adverse events
0 / 780 / 67

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026